Literature DB >> 8820476

Possible role of the intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction.

I S Sketris1, M R Wright, M L West.   

Abstract

Clarithromycin is a macrolide antibiotic similar in structure to erythromycin, but suggested to have fewer drug interactions. Although a pharmacokinetic interaction between clarithromycin and cyclosporine was recently reported, its magnitude and mechanism have not been explored. A 43-year-old renal transplant recipient receiving cyclosporine was treated with clarithromycin because of pneumonia. A cyclosporine pharmacokinetic study was performed 8 days after the initiation of the clarithromycin and 14 days after stopping the drug. Clarithromycin coadministration caused an approximately 2-fold increase in the area under the whole blood concentration versus time curve of cyclosporine. The oral clearance of cyclosporine was halved by clarithromycin, but the terminal elimination rate constant decreased only 15% and mean residence time 20%. These observations suggest that clarithromycin inhibits not only the hepatic metabolism but also the intestinal metabolism of cyclosporine. Caution is advised when administering the two drugs concurrently, and additional studies are necessary to elucidate the mechanism of this interaction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8820476

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  8 in total

Review 1.  Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients.

Authors:  N Principi; S Esposito
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

Review 2.  Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Authors:  H D Langtry; R N Brogden
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of clarithromycin.

Authors:  K A Rodvold
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

4.  Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.

Authors:  Masato Saito; Norio Yasui-Furukori; Tsukasa Uno; Takenori Takahata; Kazunobu Sugawara; Akihiro Munakata; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

Review 5.  Clinical pharmacology: special safety considerations in drug development and pharmacovigilance.

Authors:  Kwame N Atuah; Dyfrig Hughes; Munir Pirmohamed
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 6.  Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

Authors:  Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L McLeod
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

Review 7.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

8.  Outcomes Following Macrolide Use in Kidney Transplant Recipients.

Authors:  Rachel Jeong; Robert R Quinn; Krista L Lentine; Anita Lloyd; Pietro Ravani; Brenda Hemmelgarn; Branko Braam; Amit X Garg; Kevin Wen; Anita Wong-Chan; Sita Gourishankar; Ngan N Lam
Journal:  Can J Kidney Health Dis       Date:  2019-02-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.